Mold-Tek Packaging Limited — Investor Meet, 10-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

1. Financial Performance: Mold-Tek Packaging reported a 15% increase in sales for Q3 FY ’25, with a volume increase of 7.5%. Revenue reached ₹XX crores, while the EBITDA rose by 12%. However, due to higher depreciation and interest costs, profit after tax (PAT) fell by 3.9% year-over-year. Notably, the pharma segment demonstrated growth, showing revenue growth from ₹1 crore in Q2 to ₹2.27 crores in Q3, with January 2025 reflecting a strong trajectory.

2. Future Outlook and Growth Drivers: Management highlighted upcoming growth in the pharma segment, expecting revenue to increase significantly due to expanded capabilities and new product launches. The capacity utilization in the pharma domain has already reached about 40%, with plans for further enhancements to support ongoing demand.

3. Order Book and Operational Updates: The company is actively addressing supply chain challenges, including delays in printing machines and molds, crucial for the food and FMCG sectors. New machinery is expected to boost production by 35%-40% by end-February, facilitating a timely response to upcoming seasonal demands.

4. Analyst Q&A Insights (Detailed):

- **Revenue and Profitability**: Analysts probed revenue projections and were reassured by management's confidence in double-digit growth, particularly in pharma, citing potential increases in the EBITDA per kg in Q4.

- **Market Position and Competitive Landscape**: Concerns raised about losing market share to competitors like Asian Paints were met with confidence, emphasizing strong relationships and ongoing collaboration that reinforces their competitive edge.

- **Operational Challenges or Risks**: Supply chain issues were candidly acknowledged, particularly in regards to machinery and molds, but management expressed optimism about overcoming these obstacles with recent arrivals of critical equipment.

- **Capex and Capital Allocation**: Plans for capital expenditures focused on pharma segment expansions, with estimated investments between ₹30 crores to ₹40 crores for FY '26.

- **Strategic Priorities and Long-Term Vision**: The strategy emphasizes innovation in packaging, continuous product development, and enhancing automation capabilities.

5. Market or Regulatory Updates: No significant regulatory updates were discussed during the call, but management noted improving market conditions that favor the adoption of advanced packaging solutions.

6. Strategic Focus Areas: The focus remains on leveraging high-margin opportunities in pharma, maintaining robust relationships within the paint industry, and driving innovation through technological investments.

7. Investor Insight: The financial health appears promising, with tangible growth in the pharma sector and a solid margin outlook. The current trajectory suggests a 'buy' position, especially considering management's confidence in overcoming operational challenges and capturing new markets.